VivoSeq
Metabolic & Endocrine

Non-Alcoholic Steatohepatitis (NASH)

2

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Non-alcoholic Steatohepatitis (NASH) is an early-stage landscape with 2 programs across 4 companies. The most active players are Haisco Pharmaceutical Group Co., Ltd., Boston Pharmaceuticals, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.

1 program

Phase 2B

Boston Pharmaceuticals

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2GSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

HSK31679

Haisco Pharmaceutical Group Co., Ltd.

Efimosfermin

Boston Pharmaceuticals

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Protein / enzyme150%

Modality classified for 67% of 3 pipeline programs.

Analysis

Trial Status

2

clinical trials

Completed2 · 100%

Clinical Trials

Trial Activity

A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With a Single Arm Open-label Extension
Completed·GSK logoGSK·Phase 2·NCT04880031·231 enrolled
A Multicenter, Double-blind, Placebo Randomized , Phase2b Study to Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH).
Completed·Haisco Pharmaceutical Group Co., Ltd. logoHaisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT06168383·186 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)